FIXa:AT Complexes May Be Biomarker for Disease Severity in COVID-19
Researchers sought to determine the role of FIXa:AT complexes in the pathogenesis of the prothrombotic state in patients with COVID-19.
Researchers sought to determine the role of FIXa:AT complexes in the pathogenesis of the prothrombotic state in patients with COVID-19.
Researchers sought to determine whether a decision aid tool could help survivors of Hodgkin lymphoma understand lung cancer screening.
Researchers sought to determine whether a third dose of the BNT162b2 mRNA vaccine against COVID-19 may induce an antibody response in patients with CLL or SLL.
The excess risk of cancer appeared to be associated with the severity of heart failure.
Researchers sought to determine whether vaccination against COVID-19 would increase the risk of developing deep vein thrombosis.
The 12-month progression-free survival rate was superior in the lurbinectedin arm.
The combinations conferred benefits in nonsquamous non-small cell lung cancer only.
Researchers are evaluating whether specific anticancer therapies affect antibody levels.
Researchers sought to determine the mortality rate for pediatric patients with COVID-19 or multisystem inflammatory syndrome in children who experience thrombotic events.
About 31% of the articles analyzed contained information classified as harmful.